Literature DB >> 12859252

Variations in aggrecan structure modulate its susceptibility to aggrecanases.

Peter J Roughley1, James Barnett, Fengrong Zuo, John S Mort.   

Abstract

Proteoglycan aggregates and purified aggrecan from adult and fetal bovine cartilage and adult and neonatal human cartilage were subjected to in vitro degradation by recombinant aggrecanase-1 and aggrecanase-2. The ability of the aggrecanases to cleave within the aggrecan IGD (interglobular domain) and CS2 domain (chondroitin sulphate-rich domain 2) was monitored by SDS/PAGE and immunoblotting. Aggrecanase-2 showed a similar ability to cleave within the IGD of adult and immature aggrecan, whereas aggrecanase-1 was less efficient in cleavage in the IGD of immature aggrecan, for both the bovine and the human substrates. Both aggrecanases showed a similar ability to cleave within the CS2 domain of bovine aggrecan irrespective of age, but showed a much lower ability to cleave within the CS2 domain of human aggrecan. Equivalent results were obtained whether aggrecan was present in isolation or as part of proteoglycan aggregates. When proteoglycan aggregates were used, neither aggrecanase was able to cleave link protein. Thus, for aggrecan cleavage by aggrecanases, variations in cleavage efficiency exist with respect to the species and age of the animal from which the aggrecan is derived and the type of aggrecanase being used.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12859252      PMCID: PMC1223671          DOI: 10.1042/BJ20030609

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  42 in total

1.  Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4.

Authors:  J D Sandy; J Westling; R D Kenagy; M L Iruela-Arispe; C Verscharen; J C Rodriguez-Mazaneque; D R Zimmermann; J M Lemire; J W Fischer; T N Wight; A W Clowes
Journal:  J Biol Chem       Date:  2001-01-26       Impact factor: 5.157

2.  ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors.

Authors:  Juan Carlos Rodríguez-Manzaneque; Jennifer Westling; Shelley N-M Thai; Alfonso Luque; Vera Knauper; Gillian Murphy; John D Sandy; M Luisa Iruela-Arispe
Journal:  Biochem Biophys Res Commun       Date:  2002-04-26       Impact factor: 3.575

3.  Procollagen II amino propeptide processing by ADAMTS-3. Insights on dermatosparaxis.

Authors:  R J Fernandes; S Hirohata; J M Engle; A Colige; D H Cohn; D R Eyre; S S Apte
Journal:  J Biol Chem       Date:  2001-06-14       Impact factor: 5.157

4.  Cloning and characterization of ADAMTS-14, a novel ADAMTS displaying high homology with ADAMTS-2 and ADAMTS-3.

Authors:  Alain Colige; Isabel Vandenberghe; Marc Thiry; Charles A Lambert; Jozef Van Beeumen; Shi-Wu Li; Darwin J Prockop; Charles M Lapiere; Betty V Nusgens
Journal:  J Biol Chem       Date:  2001-12-07       Impact factor: 5.157

5.  Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family.

Authors:  I Abbaszade; R Q Liu; F Yang; S A Rosenfeld; O H Ross; J R Link; D M Ellis; M D Tortorella; M A Pratta; J M Hollis; R Wynn; J L Duke; H J George; M C Hillman; K Murphy; B H Wiswall; R A Copeland; C P Decicco; R Bruckner; H Nagase; Y Itoh; R C Newton; R L Magolda; J M Trzaskos; T C Burn
Journal:  J Biol Chem       Date:  1999-08-13       Impact factor: 5.157

6.  Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo.

Authors:  J D Sandy; C Verscharen
Journal:  Biochem J       Date:  2001-09-15       Impact factor: 3.857

7.  ADAMTS4 cleaves at the aggrecanase site (Glu373-Ala374) and secondarily at the matrix metalloproteinase site (Asn341-Phe342) in the aggrecan interglobular domain.

Authors:  Jennifer Westling; Amanda J Fosang; Karena Last; Vivian P Thompson; Kathy N Tomkinson; Tracy Hebert; Thomas McDonagh; Lisa A Collins-Racie; Edward R LaVallie; Elisabeth A Morris; John D Sandy
Journal:  J Biol Chem       Date:  2002-02-19       Impact factor: 5.157

8.  The mechanism of aggrecan release from cartilage differs with tissue origin and the agent used to stimulate catabolism.

Authors:  Robert Sztrolovics; Robert J White; Peter J Roughley; John S Mort
Journal:  Biochem J       Date:  2002-03-01       Impact factor: 3.857

9.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

10.  Keratan sulfate disaccharide composition determined by FACE analysis of keratanase II and endo-beta-galactosidase digestion products.

Authors:  A H Plaas; L A West; R J Midura
Journal:  Glycobiology       Date:  2001-10       Impact factor: 4.313

View more
  8 in total

1.  Osteopontin can decrease the expression of Col-II and COMP in cartilage cells in vitro.

Authors:  Yingxia Zhang; Tiansheng Wang; Yu Cao
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Selective and non-selective metalloproteinase inhibitors reduce IL-1-induced cartilage degradation and loss of mechanical properties.

Authors:  Christopher G Wilson; Ashley W Palmer; Fengrong Zuo; Elsie Eugui; Stacy Wilson; Rebecca Mackenzie; John D Sandy; Marc E Levenston
Journal:  Matrix Biol       Date:  2006-11-11       Impact factor: 11.583

3.  Involvement of ADAMTS5 and hyaluronidase in aggrecan degradation and release from OSM-stimulated cartilage.

Authors:  M Durigova; L Troeberg; H Nagase; P J Roughley; J S Mort
Journal:  Eur Cell Mater       Date:  2011-01-12       Impact factor: 3.942

4.  MMPs are less efficient than ADAMTS5 in cleaving aggrecan core protein.

Authors:  Michaela Durigova; Hideaki Nagase; John S Mort; Peter J Roughley
Journal:  Matrix Biol       Date:  2010-11-03       Impact factor: 11.583

5.  Immunohistochemical expression and distribution of proteoglycans and collagens in sclerocornea.

Authors:  Rachida Bouhenni; Michael Hart; Sabah Al-Jastaneiah; Hind AlKatan; Deepak P Edward
Journal:  Int Ophthalmol       Date:  2013-01-17       Impact factor: 2.031

6.  Aggrecan heterogeneity in articular cartilage from patients with osteoarthritis.

Authors:  John S Mort; Yeqing Geng; William D Fisher; Peter J Roughley
Journal:  BMC Musculoskelet Disord       Date:  2016-02-18       Impact factor: 2.362

7.  The role of aggrecan in normal and osteoarthritic cartilage.

Authors:  Peter J Roughley; John S Mort
Journal:  J Exp Orthop       Date:  2014-07-16

Review 8.  Keratan sulfate, a complex glycosaminoglycan with unique functional capability.

Authors:  Bruce Caterson; James Melrose
Journal:  Glycobiology       Date:  2018-04-01       Impact factor: 4.313

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.